Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.7.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents [note 4] $ 15,690 $ 15,233
Short-term investments [note 4] 760 10,230
Interest receivable   32
Amounts receivable 237 478
Prepaid expenses 765 954
Total current assets 17,452 26,927
Restricted cash [note 4 and note 7] 272 272
Property and equipment, net 166 258
Other assets 13 13
Total assets 17,903 27,470
Current liabilities:    
Accounts payable 359 2,121
Accrued liabilities other 834 2,442
Accrued clinical liabilities 342 3,415
Accrued compensation 210 188
Current portion of long-term obligations [note 7] 55 57
Warrant liability [note 4 and note 5 [f]] 180 232
Total current liabilities 1,980 8,455
Long-term obligations, less current portion [note 7] 32 49
Total liabilities 2,012 8,504
Commitments and contingencies [note 7]
Stockholders' equity:    
Common stock, $0.001 par value, 75,000,000 shares authorized, 30,121,478 and 30,059,514 issued at March 31, 2017 and December 31, 2016, respectively, and 30,087,485 and 30,025,521 outstanding at March 31, 2017 and December 31, 2016, respectively 30 29
Additional paid-in capital 213,450 213,239
Accumulated deficit (200,230) (196,942)
Accumulated other comprehensive income 2,641 2,640
Total stockholders' equity 15,891 18,966
Total liabilities and stockholders' equity $ 17,903 $ 27,470